In the news
Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.
NeuMoDx™ platforms are built to handle large volumes of sample in an automated fashion, integrating the entire molecular diagnostic process from sample to result. Dr. Steven Young, Director of Research and Clinical Trials at TriCore Reference Laboratories, has been working with NeuMoDx™ on an invitro diagnostics test approved by the FDA, using our instrumentation. Let Dr....
The NeuMoDx™ 96 and 288 Molecular Systems were formally launched at the QIAGEN booth at ESCV 2018 in Athens, Greece, provided robust feedback from clinicians, researchers, lab workers and industry members. Listen to what people are saying about our systems by watching the video below.
The NeuMoDx™ 288 Molecular System is designed for the automated extraction and isolation of nucleic acids, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. The NeuMoDx™ 288 Molecular System consists of the instrument with touchscreen computer, accessories and reagents and consumables. Learn more about the NeuMoDx™ 288...
NeuMoDx™ plans to deliver 11 CE-IVD assays to QIAGEN by the end of 2019 on NeuMoDx™ System as part of aggressive menu expansion plans, including blood-borne viruses, women’s health and transplantation assays Hilden, Germany, and Ann Arbor, Michigan, April 11, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx™ Molecular, Inc....
